Tech Support


This line is for technical support.
For General Enquiries please click General Contact

ADA 2019 - CrownBio Posters

Booth #2119


We presented two posters on NASH development in the MS-NASH mouse (formerly FATZO) at ADA 2019. The MS-NASH mouse is an inherently dysmetabolic, obese, and diabetic model, allowing human disease-relevant NAFLD/NASH development in the context of dysmetabolism. This provides a highly translational mouse model for preclinical NASH studies.


Progressive Liver Dysfunction Resulted from a High-Fat, High-Fructose Diet in MS-NASH (FATZO) Mice

Poster Session: 22-A Obesity–Animal
Date & Time: Monday Jun 10, 2019 12:00 PM - 1:00 PM
Presented by: Dr Yong-Fu Xiao, Senior Director, Cardiovascular and Metabolic Disease Research

Learn more about NASH development in the MS-NASH mouse through administration of a Western diet plus fructose. Review the liver dysfunction induced including elevated AST, ALT, and ALP, and model utility for preclinical NASH studies.



Accelerated Hepatic Fibrosis in Western Diet-Fed Nonalcoholic Steatohepatitis Mice Model by Small Dosage of Carbon Tetrachloride

Poster Session: 22-A Obesity–Animal
Date & Time: Sunday Jun 9, 2019 12:00 PM - 1:00 PM
Presented by: Dr Guodong Zhang, Director of Crown Bioscience Louisiana Inc.

Explore accelerated NASH development in the MS-NASH (FATZO) mouse, through the extra addition of CCl4. Review exacerbated disease pathology, including fibrosis, in this inherently dysmetabolic background. Discover model characterization and improved outcomes following treatment with obeticholic acid.


Presentations using CrownBio Models

Controlled-Release Mitochondrial Protonophore (CRMP) Reverses Hypertriglyceridemia and Hepatic Steatosis in Dysmetabolic Nonhuman Primates

Presentation Session: New Agents and Strategies
Date & Time: Friday June 7, 2019 4:45pm
Presented by: Dr Leigh Goedeke, Postdoctoral Fellow at Yale University School of Medicine

Learn more about a controlled-release mitochondrial protonophore, that produces mild liver-targeted mitochondrial uncoupling, and the decrease in hypertriglyceridemia and NASH it induces in dysmetabolic NHPs. Explore how NHP study data offers proof of concept for the development of liver-targeted mitochondrial uncoupling agents as a potential novel therapy for hypertriglyceridemia, NASH, and diabetes.

Request Time To Discuss a Poster

Your privacy is important to us.
We'll never share your information.